Ameriprise
TPTX

Ameriprise’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Ameriprise’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,576
Closed -$2M – 4077
2022
Q2 		$2M Buy
+26,576
New +$1.18M ﹤0.01% 2807
2021
Q4 		– Sell
-119,914
Closed -$7.97M – 4082
2021
Q3 		$7.97M Buy
+119,914
New +$8.54M ﹤0.01% 2045
2020
Q4 		– Sell
-75,616
Closed -$6.61M – 3854
2020
Q3 		$6.61M Sell
75,616
-28,647
-27% -$2M ﹤0.01% 1878
2020
Q2 		$6.73M Buy
104,263
+23,171
+29% +$1.34M ﹤0.01% 1845
2020
Q1 		$3.62M Sell
81,092
-257
-0.3% -$13.6K ﹤0.01% 2121
2019
Q4 		$5.07M Buy
81,349
+65,722
+421% +$3.13M ﹤0.01% 2222
2019
Q3 		$587K Sell
15,627
-24,125
-61% -$1.05M ﹤0.01% 3248
2019
Q2 		$1.62M Buy
+39,752
New +$1.42M ﹤0.01% 2861

Ameriprise's TPTX Position: Q3 2022 in Review

Ameriprise sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 26,576 shares — an estimated $2M sold.

Ameriprise first reported a position in TPTX in Q2 2019 and held it in 8 quarters. The position peaked at $7.97M in Q3 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Ameriprise reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Ameriprise sold 26,576 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2M.
  • Ameriprise first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • Ameriprise's Turning Point Therapeutics, Inc. Common Stock position peaked at $7.97M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Ameriprise's 13F filing for Q3 2022, filed 14 Nov 2022.